Aurora Cannabis (ticker: ACB)
Aurora Cannabis shares traded in April as low as 60 cents. Aurora also announced a $250 million equity facility that could dilute shareholders by more than 30%. But Cantor Fitzgerald analyst Pablo Zuanic says Aurora’s first-quarter earnings report was a much-needed indication of potential profitability. Aurora management also said the $250 million equity facility was merely a precaution and would likely not be used. Finally, Aurora announced a buyout of U.S. CBD company Reliva, suggesting that Aurora’s financial situation isn’t as terrible as some investors thought. Cantor Fitzgerald has an “overweight” rating and $19.29 price target for ACB stock.